http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H05255104-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 |
| filingDate | 1992-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1993-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H05255104-A |
| titleOfInvention | Cytostatic factor |
| abstract | (57) [Summary] (Modified) [Objective] To provide a cell growth inhibitor derived from bovine brain. [Structure] A cation exchanger-adsorbing glycoprotein obtained by treating bovine brain with trypsin, and having a molecular weight of about 12,000, 90 by SDS-polyacrylamide gel electrophoresis. It exhibits thermostability at 30 ° C for 30 minutes, and adrenal pheochromocytoma (PC-1 A substance showing a specific inhibitory activity to 2). [Effect] The above-mentioned cell growth factor is effective as an agent for improving brain dysfunction in improving Alzheimer's disease, dementia, memory impairment, aphasia, apraxia, mental illness, and hepatic encephalopathy. In addition, it is expected to have an inhibitory effect on malignant neoplastic diseases. |
| priorityDate | 1992-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 143.